Drugs / Insulatard

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Insulatard 2002-10-07 europa.eu

Trials 3 · a red edge is where a trial was stopped

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01756105 Jun 2012 → Feb 2018 gestational diabetes University Hospital, Strasbourg, France Terminated No outcome recorded
Phase 41 trial
Phase 4 NCT00329615 Jan 2000 → Sep 2005 Göteborg University Completed No outcome recorded
Phase not applicable1 trial
NCT00506194 Oct 2005 → Aug 2007 type 2 diabetes mellitus Taipei Veterans General Hospital, Taiwan Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00830297 Comparator Jan 2009 → Dec 2010 hyperglycemia Marcus Saemann Completed No outcome recorded
Phase 43 trials
Phase 4 NCT06855615 Comparator Oct 2020 → Jan 2021 type 2 diabetes mellitus Hospital Sultanah Aminah Johor Bahru Completed No outcome recorded
Phase 4 NCT00788840 Comparator Jan 2008 → Aug 2009 obesity disorder, type 2 diabetes mellitus University of Surrey Completed No outcome recorded
Phase 4 NCT00566124 Comparator Jan → May 2005 diabetes mellitus University of Aarhus Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as insulatard “Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard.” NCT00506194
6

“introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping” NCT01756105

NCT00788840

NCT00329615

NCT06855615

NCT00566124

NCT00830297

Modality Protein / enzyme biologic “Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.” NCT00788840
Route Subcutaneous “injected s.c. in the thigh” NCT00566124